Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Short-term Investments (2025)

Neuphoria Therapeutics (NEUP) has disclosed Short-term Investments for 1 consecutive years, with $79647.0 as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $79647.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $79647.0, a N/A change, with the full-year FY2025 number at $77945.0, changed N/A from a year prior.
  • Short-term Investments was $79647.0 for Q4 2025 at Neuphoria Therapeutics, up from $78564.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $79647.0 in Q4 2025 to a low of $77945.0 in Q2 2025.